Product delay hits Cedara profits

Article

A product roll-out delay is the reason Cedara Software gave for its disappointing third quarter 2000 profits. The company's net loss was $119,000 (Canadian), compared to net income of $385,000 in the third quarter of 1999. Revenue for third

A product roll-out delay is the reason Cedara Software gave for its disappointing third quarter 2000 profits. The company's net loss was $119,000 (Canadian), compared to net income of $385,000 in the third quarter of 1999. Revenue for third quarter 2000 was $15.9 million, compared to $12.3 million for the same period a year earlier.

A new platform, the SNN 3.0, which integrates multiple surgical software systems, was not shipped to installed base customers until March 31, and was launched on the market immediately thereafter.

Cedara makes software for diagnostic imaging, image management, image-guided therapy, and cardiology. It recently released both Internet streaming software for medical imaging, called Cedara directDICOM, and Image Management Business for the PACS market.

Another factor affecting Cedara's earnings, according to a company statement, was losses for Surgical Navigation Specialists, in which Cedara has a minority interest. The company believes it will recover this loss from SNS profits in future quarters.

Cedara chairman and CEO Michael Greenberg said in a statement, "We have a backlog of orders for the SNN 3.0 platform. Despite the delay in shipping surgical systems, our R&D investment in growth markets is showing its potential."

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.